CorNav Corporation Collaborates with Mayo Clinic on New Ventricular Tachycardia Treatment

The goal of this new agreement is to help CorNav more effectively develop the means to address this important unmet need and improve the epicardial treatment of VT that afflicts millions of people in the United States and around the world, explains James Fonger, M.D., founder and CEO.